生物谷博客正在载入数据,请稍等...
 标签:| siRNA | miRNA | piRNA |文献|电子书|生物视频|Nature杂志|Science杂志|核酸技术|蛋白技术|博主推荐|Click≥100|SCI|文献检索
与我联系
       点击这里给我发消息
搜索本站
合作伙伴
站点信息
生物谷博客正在载入数据,请稍等...
                  友情链接          more
本站LOGO
最新日志
生物谷博客正在载入数据,请稍等...
广而告之
生物谷博客正在载入数据,请稍等...
 谷歌订阅  Blogines订阅  抓虾订阅  鲜果订阅  
       使用RSS邮天下订阅  
「 Science----基因疗法改善了四位病人的视力Gene Therapy Improves Sig 」
→无名 发表于 2008-4-30 20:44:00
Gene Therapy Improves Sight of Four Patients
By Jocelyn Kaiser

ScienceNOW Daily News
28 April

In what eye researchers are hailing as a major advance, gene therapy has partially restored the sight of four young adults born with severe blindness. In two small studies, the patients' ability to sense light improved, and two can now read several lines of an eye chart. All are still legally blind, but the same treatment could potentially prevent this type of blindness in babies.
The four patients have a disease called Leber congenital amaurosis (LCA), an inherited disorder affecting about 3000 Americans that begins at birth and leads to complete blindness by age 40. Researchers blame one form of the disease on a mutation in a gene called retinal pigment epithelium 65 (RPE65). The protein encoded by the gene helps convert vitamin A into a form used by the retina's light-sensing cells (rods and cones) to make rhodopsin, a pigment that absorbs light. Without rhodopsin, these photoreceptor cells eventually die. In 2001, researchers reported that giving retina cells a working copy of RPE65 restored photoreceptor function in blind Briard dogs with the RPE65 mutation. After a gene-therapy injection, the dogs could avoid objects and walk through a maze (ScienceNOW, 27 April 2001).

Now researchers have tested the treatment in six patients ages 17 to 26 with the RPE65 defect. At Children's Hospital of Philadelphia, University of Pennsylvania (Penn) gene-therapy researcher Jean Bennett's team injected one eye of each patient with a harmless virus modified to carry the RPE65 gene. The gene therapy did not appear to cause side effects. (One patient's retina developed a small hole, but it didn't affect vision.) A few weeks later, a test based on pupil constriction showed that the patients could detect three times more light. Two patients who could see only hand motions before were able to read several lines of an eye chart. And one patient was able to navigate an obstacle course efficiently for the first time.

In a similar safety study at University College London, Robin Ali's team saw improvement in only one of three patients--the one with the most intact retinal tissue, an 18-year-old, Ali says. He was no better at reading an eye chart, but his light perception improved 100-fold. In a video before treatment, he stumbles through a simulated night street scene, bumping into walls several times in 77 seconds. Six months after the injection, he breezes through in 14 seconds. "It's more than we could have hoped for," Ali says. Both teams reported their findings online yesterday in the New England Journal of Medicine and presented them yesterday and today at the annual meeting of the Association for Research in Vision and Ophthalmology in Fort Lauderdale, Florida.

Although these studies were only designed to test safety, the results are "exciting," says Paul Sieving, director of the National Eye Institute (NEI). "There is certainly a suggestion of efficacy." NEI is funding a third study based on the same gene therapy at Penn and at the University of Florida that also has "very encouraging" results, says principal investigator Samuel Jacobson of Penn, but it is not yet ready for publication.

The London and Philadelphia teams are now planning to treat younger LCA patients, who have better preserved retinas and so could benefit even more. Eventually, in order to prevent blindness altogether, "you need to treat babies," says neurobiologist Dean Bok of the University of California, Los Angeles.

Meanwhile, researchers are thinking about gene-therapy trials for other inherited retinal diseases as well as for more common disorders such as macular degeneration. If the LCA findings hold up, "it will open the floodgates for therapies for other diseases," says eye-disease geneticist Stephen Daiger of the University of Texas Health Science Center in Houston.

                 关于部分日志中包含的文件不能下载的说明
收藏到:| 新浪vivi | 天极网摘 | QQ书签 | 和讯网摘 | 365Key | 雅虎收藏 | 百度搜藏 | 收客网 |
阅读全文 | 回复(0) | 引用通告 | 编辑  」
发表评论:
生物谷博客正在载入数据,请稍等...
为何选择Firefox浏览器?用Firefox火狐浏览器有什么好处?
最新留言
生物谷博客正在载入数据,请稍等...
最新评论
生物谷博客正在载入数据,请稍等...
使用Google搜索网络
Google


为什么选择Google广告


有建议这里留言


肿瘤基因治疗论坛介绍
上网好帮手!        MYKOO网博客推广专家 橱窗博客        【中文博客之家】Bloge.org.cn 打造缤纷炫丽的家园,展示万千博客的风采!
           365bloglink - 博邻    
Powered by Oblog.